Oxaliplatin
اگزالیپلاتین
🎗️ Antineoplastic And Immunomodulating AgentsPlatinum compound
Market / country: 🇺🇸 USA
Eloxatin (US)
🧮 Dose calculator
Colorectal cancer · Regimen source: FDA Oxaliplatin · 2.1
- • Concurrently with leucovorin 200 mg/m² (separate bag), then fluorouracil. Adjuvant up to 12 cycles. Prolong to 6 h for acute infusion reactions. FDA Oxaliplatin · 2.1FDA Oxaliplatin · 2.2
- • Only under an oncologist in an equipped centre. Calculator = label mg/m² × BSA (Mosteller); protocol, cycle interval and adjustment for CBC and renal/hepatic function rest with the oncology team. FDA Oxaliplatin · 2.1
Enter age and weight.
🛡️ Safety & information
Contraindications
- ⛔ History of hypersensitivity to oxaliplatin or other platinum drugs. FDA Oxaliplatin · 4
Warnings
- • Boxed warning: serious and fatal hypersensitivity/anaphylaxis in any cycle — stop permanently. FDA Oxaliplatin · Boxed Warning
- • Sensory neuropathy (cold-induced); severe myelosuppression; PRES; pulmonary and hepatic toxicity; QT; rhabdomyolysis; haemorrhage; embryo-fetal toxicity. FDA Oxaliplatin · 5
Renal adjustment
- • eGFR < 30: CrCl <30: 65 mg/m². FDA Oxaliplatin · 2.3
Formulations
- 5 mg/mL (50/100/200 mg) — injection 🇺🇸 USA FDA Oxaliplatin · 3
👥 Special populations
- 🤰 PregnancyDangerous / avoid
Label: can cause fetal harm. Dangerous in pregnancy. FDA Oxaliplatin · 8.1
“Risk Summary Based on its direct interaction with DNA, oxaliplatin can cause fetal harm when administered to a pregnant woman.”
- 🤱 BreastfeedingDangerous / avoid
Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Oxaliplatin · 8.2
“Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with oxaliplatin and for 3 months after the final dose.”
- 👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Oxaliplatin · 8.4
“The safety and effectiveness of oxaliplatin in pediatrics have not been established.”
- 👴 Older adultsNo specific problem stated
Label: no specific difference or dose adjustment stated for older adults. FDA Oxaliplatin · 8.5
“No overall differences in effectiveness were observed between these patients and younger adults.”
- ⚥ Females & males of reproductive potentialUse with caution
Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Oxaliplatin · 8.3
“Contraception Oxaliplatin can cause embryo-fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ] .”
🔗 Reference links
- FDA (approval record)ANDA207325
- DailyMed (FDA label)FDA Oxaliplatin
- MedlinePlus (NIH)Oxaliplatin Injection
- WHO ATC/DDDL01XA03
- Darooyab (Iran)Oxaliplatin
🇮🇷 Registered in Iran Darooyab · G-1043/Oxaliplatin
Dosage forms with Iranian generic codes, per Darooyab.
- 01916 · OXALIPLATIN 100MG VIAL · ویال اگزالیپلاتین ۱۰۰ میلیگرم
- 07040 · OXALIPLATIN 100MG/20ML VIAL · ویال اگزالیپلاتین ۱۰۰ میلیگرم / ۲۰ میلیلیتر
- 09749 · OXALIPLATIN 200MG VIAL · ویال اگزالیپلاتین ۲۰۰ میلیگرم
- 01915 · OXALIPLATIN 50MG VIAL · ویال اگزالیپلاتین ۵۰ میلیگرم
- 07041 · OXALIPLATIN 50MG/10ML VIAL · ویال اگزالیپلاتین ۵۰ میلیگرم / ۱۰ میلیلیتر
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Oxaliplatin · 3FDA Oxaliplatin · 2.1FDA Oxaliplatin · 2.2FDA Oxaliplatin · 4FDA Oxaliplatin · Boxed WarningFDA Oxaliplatin · 5FDA Oxaliplatin · 2.3FDA Oxaliplatin · SPL approval / marketing categoryFDA Oxaliplatin · 8.1FDA Oxaliplatin · 8.2FDA Oxaliplatin · 8.4FDA Oxaliplatin · 8.5FDA Oxaliplatin · 8.3
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-1043/Oxaliplatin
- Clinical review⚠ Unverified